Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates

Financial Performance - Mirum Pharmaceuticals reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of a loss of $0.10 per share, and showing improvement from a loss of $0.30 per share a year ago, resulting in an earnings surprise of +150.00% [1] - The company achieved revenues of $133.01 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.85% and increasing from $90.38 million in the same quarter last year [2] Stock Performance - Mirum Pharmaceuticals shares have increased approximately 71.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $137.68 million, and for the current fiscal year, it is -$0.67 on revenues of $508.94 million [7] - The Medical - Biomedical and Genetics industry, to which Mirum Pharmaceuticals belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]